High-dose interleukin-2 therapy related adverse events and implications on imaging
- 20 September 2021
- journal article
- research article
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 27 (5), 684-689
- https://doi.org/10.5152/dir.2021.20503
Abstract
High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) and metastatic melanoma. IL-2 is able to promote CD8+ T cell and natural killer (NK) cell cytotoxicity to increase tumoricidal activity of the innate immune system. HDIL-2 therapy is associated with a wide spectrum of immune-related adverse events (irAEs) that can be radiologically identified. HDIL-2 toxicity can manifest in multiple organ systems, most significantly leading to cardiovascular, abdominal, endocrine, and neurological adverse events. The collective impact of the irAEs and the rise of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors led to the demise of HDIL-2 as a primary therapy for mRCC and metastatic melanoma. However, with innovation in ICIs and the creation of mutant IL-2 conjugates, there has been a drive for combination therapy. Knowledge of the HDIL-2 therapy and HDIL-2 related adverse events with radiology relevance is critical in diagnostic image interpretation.Keywords
This publication has 9 references indexed in Scilit:
- Back to the Future: Rethinking and Retooling IL2 in the Immune Checkpoint Inhibitor EraCancer Discovery, 2019
- Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionJournal for ImmunoTherapy of Cancer, 2019
- Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 InhibitorsCurrent Oncology Reports, 2018
- Multimodality imaging of endocrine immune related adverse events: a primer for radiologistsClinical Imaging, 2018
- Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registryJournal for ImmunoTherapy of Cancer, 2017
- A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaJournal for ImmunoTherapy of Cancer, 2016
- Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapyActa Radiologica Open, 2015
- Takotsubo Cardiomyopathy: Assessment With Cardiac MRIAmerican Journal of Roentgenology, 2010
- Diffuse Gallbladder Wall Thickening: Differential DiagnosisAmerican Journal of Roentgenology, 2007